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Background. Older age at initiation of combination antiretroviral therapy (cART) has been associated with poorer clinical out-
comes. Our objectives were to compare outcomes between older and younger patients in our clinical cohort in Jos, Nigeria.
Methods. This retrospective cohort study evaluated patients enrolled on cART at the Jos University Teaching Hospital, Nigeria 
between 2004 and 2012. We compared baseline and treatment differences between older (≥50 years) and younger (15–49 years) 
patients. Kaplan-Meier analysis and Cox proportional hazard models estimated survival and loss to follow-up (LTFU) and deter-
mined factors associated with these outcomes at 24 months.
Results. Of 8352 patients, 643 (7.7%) were aged ≥50 years. The median change in CD4 count from baseline was 151 vs 132 
(P = .0005) at 12 months and 185 vs 151 cells/mm3 (P = .03) at 24 months for younger and older patients, respectively. A total of 
68.9% vs 71.6% (P = .13) and 69.6% vs 74.8% (P = .005) of younger and older patients achieved viral suppression at 12 and 24 months, 
with similar incidence of mortality and LTFU. In adjusted hazard models, factors associated with increased risk of mortality were 
male sex, World Health Organization (WHO) stage III/IV, and having a gap in care, whereas being fully suppressed was protective. 
The risk of being LTFU was lower for older patients, those fully suppressed virologically and with adherence rates >95%. Male sex, 
lack of education, WHO stage III/IV, body mass index <18.5 kg/m2, and having a gap in care independently predicted LTFU.
Conclusions. Older patients achieved better viral suppression, and older age was not associated with increased mortality or 
LTFU in this study.
Keywords. ART; HIV; LTFU; mortality; older. 
 
As more patients are placed on effective combination antiret-
roviral therapy (cART), there are a growing number of people 
aged 50 years and older living with human immunodeficiency 
virus (HIV) infection. For the first time since the start of the epi-
demic, 10% of the adult population living with HIV in low- and 
middle-income countries (LMIC) were aged 50 years or older 
at the end of 2012 [1]. Seventy-four percent of the 100 000 new 
infections occurring among people aged 50 years and above in 
LMIC annually are acquired in sub-Saharan Africa (SSA). The 
aging of the HIV epidemic can be attributed to improved sur-
vival with cART and decrease in incident cases among young 
adults and youth [2, 3].
There are special challenges for delivery and monitoring of 
older patients on cART. Data from 12 LMIC where more than 
1 in 10 people initiating ART are ≥50  years old found that 
mortality was higher in older compared with younger persons, 
with late presentation serving as an important cofactor [4, 5]. 
Older persons living with HIV are also known to experience 
higher burden of comorbidities [6–8] and are often diagnosed 
at a worse stage of HIV infection compared with their younger 
counterparts [9, 10]. Data from resource-rich settings report-
ing on cART outcomes among older patients indicate that 
despite experiencing higher rates of virologic suppression, older 
patients tend to have poorer rates of immune reconstitution and 
higher mortality compared with younger patients [8, 11–13], 
with others reporting mixed outcomes [14–16].
Studies from SSA have also reported similar outcomes to 
cART with respect to viral suppression, immunologic response, 
and survival [17–20]. In an outcomes study reporting on 7 
African countries, mortality rates were higher and loss to fol-
low-up (LTFU) rates lower among older patients [21]. However, 
this study did not present data on virologic or immunologic 
response. As more people in SSA initiate cART and live longer, 
the population of patients aged 50 years and above will increase, 
with older people remaining at increased risk of HIV acquisition 
[3]. In light of the above data, there is a need to better under-
stand the response to cART in indigenous older patients in SSA 
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and its related outcomes. Nigeria has the second highest burden 
of HIV globally [2] and is halfway into the second decade of her 
national antiretroviral therapy (ART) program. In this analysis, 
our objectives were to characterize the baseline features of older 
adults initiating cART and to report on outcomes to treatment 
in the first 2 years postinitiation in a comprehensive HIV treat-
ment, care, and support program in Jos, north central Nigeria.
MATERIALS AND METHODS
This observational retrospective analysis was conducted using 
data collected routinely at the HIV clinic at the Jos University 
Teaching Hospital (JUTH), north central Nigeria. (1) The 
Government of Nigeria and (2) the US President’s Emergency 
Plan for AIDS Relief (PEPFAR) through a grant awarded to 
the Harvard T.H. Chan School of Public Health and the AIDS 
Prevention Initiative Nigeria, Ltd/Gte (APIN) jointly funded 
the program. For this evaluation, we accessed routine clinical 
data collected for patients enrolled for care between June 2004 
and February 2012.
Inclusion criteria for this evaluation were age ≥15  years, 
ART-naive at enrollment, not pregnant at the time of enroll-
ment, and not having HIV-2 or dual HIV-1/HIV-2 infection. 
Patients were excluded if they received cART for less than 48 
weeks and/or had less than 24 months of follow-up (Figure 1). 
Patients were seen regularly after enrollment and cART initia-
tion. Hepatitis B virus (HBV) surface antigen (Monolisa HBsAg 
Ultra3; Bio-Rad, France), and hepatitis C virus (HCV) anti-
body (DIA.PRO Diagnostic, Bioprobes srl, Milan, Italy) assess-
ments were conducted at baseline. Immunonologic monitoring 
with CD4+ cell counts using flow cytometry (Partec, Munster, 
Germany) and HIV viral load (VL) assays were also performed 
routinely (Cobas Amplicor Monitor Assay, version 1.5; Roche 
Diagnostics, Mannheim, Germany). Patients were initiated on 
cART according to the National guidelines existing at the time 
of program entry (CD4+ cell count <200 cells/mm3, clinical 
WHO stage III/IV or clinical WHO stage III/IV with CD4+ cell 
count of <350 cells/mm3) with 1 nonnucleoside reverse-tran-
scriptase inhibitor (NNRTI) and 2 nucleoside reverse-tran-
scriptase inhibitors (NRTIs). During the period covered by this 
study, standard first-line ART regimens included stavudine or 
zidovudine (AZT) with abacavir (ABC) and tenofovir (TDF) 
as alternative options for NRTI and nevirapine or efavirenz as 
NNRTI options. At each visit, patients received adherence and 
nutrition counseling and ART refills. Monitoring laboratory 
tests, including hemoglobin (Hb), serum creatinine, and ala-
nine aminotransferase (ALT), in addition to CD4+ cell counts 
and VLs were performed at 3 and 6 months, then 6-monthly 
thereafter. Hypertension was defined as systolic blood pres-
sure ≥140  mm Hg or diastolic blood ≥90  mm Hg or the use 
of antihypertensive medications. Diabetes mellitus was defined 
as fasting plasma glucose ≥126 mg/dL, or use of hypoglycemic 
drugs).
Data Collection
Patient demographic, clinical, laboratory, and therapeutic data 
were collected on standard forms at enrollment and at each 
follow-up visit. Data were entered into a secure computerized 
database designed solely for the purpose of patient care man-
agement [22]. The database was updated daily by data entry 
clerks, and the data management team ensured data accuracy 
by performing weekly quality assurance checks of the databases. 
Data collected for this study included baseline demographics, 
weight, height, World Health Organization (WHO) clinical 
stage, ART regimen at initiation, enrollment and visit dates, 
and date of discontinuation (either by death, LTFU, transfer, or 
self-withdrawal). Baseline and follow-up laboratory monitoring 
and drug use data were also collected.
Ethical Consideration
All patients in the Harvard/APIN program provided written 
consent for care. Only those who consented to the use of their 
information for research were included in this analysis. All 
patient data were delinked and deidentified. Institutional review 
boards at the Harvard T. H. Chan School of Public Health and 
the Jos University Teaching Hospital approved the use of data 
for this study.
Figure 1. Flowchart of patients evaluated and included in this study. ART, antiret-
roviral therapy; ARV, antiretroviral; HIV, human immunodeficiency virus; JUTH, Jos 
University Teaching Hospital. 
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Outcomes of Interest
The primary treatment outcomes were immunologic and viro-
logic responses to cART at 6, 12, 18, and 24 months postinitia-
tion with the main clinical outcomes being all-cause mortality 
(irrespective of time of cART initiation) and LTFU. A patient 
was considered LTFU if he/she had not attended the facility 
for a medication refill, a laboratory visit, or a clinicians visit in 
the 180  days preceding data abstraction. Mortality ascertain-
ment occurred largely through passive reporting to the health 
facility by family or friends and, to a lesser extent, through 
site-specific tracing activities to locate patients LTFU. If the 
date of death was unknown, but a patient was known to have 
died, the date of the last encounter with the patient was used 
as the date of death. Other outcomes of interest included the 
incidence of select laboratory abnormalities post-cART initia-
tion (Hb ≤8 g/dL, ALT ≥120 IU, and serum creatinine ≥260), 
rates of drug substitution, and calculated average medication 
adherence rates. Immunologic outcomes observed were the 
median change in CD4+ cell count over time from baseline. We 
also assessed the absolute cell increase from baseline to each 
time point. Virologic response was assessed using the pro-
portion of patients with HIV VL <400 copies/mL of blood at 
each designated time point, and we assessed the proportion of 
patients achieving viral suppression from 6 through 24 months 
of therapy (fully suppressed-FS). Discontinuation was defined 
as death, LTFU, or withdrawal from the program. Time to dis-
continuation was calculated using the last recorded visit date. 
Percent adherence values were carried backward because adher-
ence is calculated at the end of a prescription refill cycle. The 
average adherence rate was calculated as the proportion of time 
the patient had pills available (number of days supplied/number 
of days between refills) and was capped at 100%. A prespecified 
adherence cutoff of ≥95% was used for categorical assessment 
of optimal adherence. A gap in treatment was defined as any 
period ≥60 days when a patient was without pills. We assessed 
the number of gaps by age group for the first year of therapy 
as well as the second year of therapy. Given that there was no 
significant difference between the age groups in the numbers 
experiencing 1 or 2 gaps per treatment year, we dichotomized 
this outcome as “any gap” in treatment versus no gap in the mul-
tivariate analysis.
Statistical Methods
Proportions, means (±standard deviation [SD]), and medians 
(interquartile ratios [IQR]) were calculated for baseline charac-
teristics at the time of cART initiation. The primary predictor 
was age at cART initiation. This was categorized as 15–49 years 
(younger) or ≥50  years (older). Immunologic and virologic 
responses at months 6, 12, 18, and 24 between the 2 groups 
were also assessed. We also determined the proportions of 
patients fully suppressed (FS) for the 2 groups and determined 
factors associated with being FS in a logistic regression model. 
We determined the incidence of laboratory abnormalities in 
the first 24  months of cART for serum creatinine, Hb, and 
ALT. Abnormal cutoffs for each were defined as at least grade 
2 according to severity grading of adult adverse events [23]. 
Finally, we determined rates of death and LTFU by age group. 
Patients were followed up until they achieved the outcomes of 
interest or the earliest among the following outcomes: death, 
LTFU, or the date December 2012 (the end of the follow-up 
period). To describe the probability of death and LTFU, we used 
Kaplan-Meier survival analysis.
To estimate the association between age group at treatment 
initiation, death, and LTFU, Cox proportional hazards models 
were used to estimate unadjusted and adjusted hazard ratios 
(aHRs) for each outcome separately with relevant covariates. 
The final Cox proportional hazards regression models included 
variables that were statistically significant as well as clinically 
relevant covariates (significant or not) in unadjusted analyses. 
Because a significant number of deaths are missed due to loss to 
follow-up in program settings in LMIC [24, 25], we constructed 
Cox proportional hazard models and estimated mortality rates 
after imputing ranked proportions (10%, 25%, and 50%) of 
patients documented to be LTFU as dead and compared these 
with the complete case model. The criterion for significance 
for analyses was 2-tailed P value <.05. Statistical analyses were 
performed with the statistical software packages Epi 7 (Centers 
for Disease Control and Prevention, Atlanta, GA) and STATA 
version 13.1 (StataCorp, College Station, TX).
RESULTS
During the period of June 2004 to February 2012, 15 654 patients 
were enrolled for cART services at JUTH. Our final cohort had 
8352 patients with 643 (7.7%) being 50 years or older at enroll-
ment (Figure  1). The baseline characteristics of patients are 
summarized in Table 1. A greater proportion of older patients 
compared with younger patients were men (P < .001). We found 
significant differences in marital status, where a higher percent-
age of older patients were married or widowed compared with 
younger patients (P < .001), and educational level, where older 
patients were less likely to have higher-level education than the 
younger patients (P  <  .001). Older patients were more likely 
than their younger counterparts to have hepatitis C coinfection 
(P = .001), hypertension (P < .001), diabetes mellitus (P < .001), 
higher Hb concentration (P =  .008), and higher serum creati-
nine (P < .001).
Median CD4+ cell counts post-cART initiation through 
24  months increased significantly for both groups (Figure  2). 
Median CD4+ counts (IQR) were higher at months 6 (272, IQR 
177–386 vs 251, IQR 166–367; P = .02), 12 (303, IQR 200–433 
vs 283, IQR 186–406; P = .004), and 24 (370, IQR 250–511 vs 
331, IQR 215–453; P =  .0001) for younger patients compared 
with older patients. Among patients with CD4+ count  <200 
cells/mm3 at baseline, 57.9% of older patients compared with 
64.5% of younger patients (P =  .004) had achieved CD4 ≥200 
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Table 1. Baseline Characteristics of Study Population (n = 8 352)
Characteristics Total (n = 8352) Young (15–49 Years) (n = 7709)
Older (≥50 Years)
(n = 643) P Value
Mean age, years (SD) 35 ± 8 33 ± 7 55 ± 5 <.001
Sex, n (%) <.001
 Male 2856 (34.2) 2486 (32.3) 370 (57.5)
 Female 5492 (65.8) 5219 (67.7) 273 (42.5)
 Missing 4 (0.0) 4 (0.0) 0 (0.0)
Marital Status <.001
 Single 1665 (19.9) 1660 (21.5) 5 (0.8)
 Married 4471 (53.5) 4079 (53.0) 392 (60.9)
 Widowed 1499 (18.0) 1296 (16.8) 203 (31.6)
 Divorced/Separated 707 (8.5) 664 (8.6) 43 (6.7)
 Missing 10 (0.1) 10 (0.1) 0 (0.0)
Educational Level Attained <.001
 No Formal Education 1400 (16.8) 1167 (15.1) 233 (36.2)
 Primary 1689 (20.2) 1547 (20.0) 142 (22.1)
 Secondary 2475 (29.6) 2415 (31.3) 60 (9.3)
 Tertiary 2692 (32.2) 2509 (32.6) 183 (28.5)
 Missing 96 (1.2) 71 (1.0) 25 (3.9)
WHO Stage .09
 I 2757 (33.0) 2565 (33.27) 192 (29.8)
 II 2698 (32.3) 2491 (32.31) 207 (32.2)
 III 2174 (26.0) 1993 (25.85) 181 (28.2)
 IV 465 (5.6) 418 (5.42) 47 (7.3)
 Missing 258 (3.1) 242 (3.14) 16 (2.5)
WHO Stage III/IV 2639 (31.6) 2411 (31.2) 228 (35.4) .02
Body mass index (kg/m2)
 Median (IQR) 21.5 (19.3–24.0) 21.5 (19.3–23.9) 22.0 (19.7–24.9) .0007
BMIb Class .002
 Underweight (<18.5) 1128 (16.1) 1046 (16.2) 82 (15.0)
 Ideal weight (18.5–24.9) 4590 (65.5) 4260 (66.0) 330 (60.3)
 Overweight (25.0–29.9) 1035 (14.8) 925 (14.3) 110 (20.1)
 Obese ≥30 250 (3.6) 225 (3.5) 25 (4.6)
Baseline CD4+ Cell Count
 Median (IQR) 136 (71–201) 136 (72–201) 139 (69–200) .75
 % With CD4 <200 5941 (71.1) 5480 (71.1) 461 (71.7) .74
Median baseline HIV RNA (cp/mL) (IQR) 53 253 (12 743–174 358) 52 527 (12 533–170 899) 70 733 (18 025–212 684) .003
Baseline Hemoglobin
 Median, g/dL (IQR) 11.0 (10–13) 11.0 (10–13) 12 (10–13) .008
 <8 g/dL, n (%) 459 (5.5) 433 (5.6) 26 (4.0) .09
Baseline ALT, median (IQR)-IU/L 24 (16–39) 25 (16–39) 24 (16–36) .22
Baseline serum creatinine, median (IQR)-µmol/L 81.0 (65.2–101.3) 80.2 (64.9–100.7) 91.3 (70.5–113.1) <.001
Median eGFRa,  mLs/min per1.73 m2 (IQR) 96.4 (74.9–116.6) 97.9 (76.2–118.0) 80.9 (63.9–101.0) <.001
HBsAg at baseline, n (%) <.001
Positive 1232 (14.7) 1168 (15.1) 64 (9.9)
Negative 4975 (59.6) 4554 (59.1) 421 (65.5)
Missing 2145 (25.7) 1987 (25.8) 158 (24.6)
Anti-HCVab at baseline, n (%) .001
Positive 911 (10.9) 811 (10.5) 100 (15.6)
Negative 5294 (63.4) 4908 (63.7) 386 (60.0)
Missing 2142 (25.7) 1990 (25.8) 157 (24.4)
Hypertension at baseline, n (%) 136 (1.6) 85 (1.1) 51 (7.9) <.001
Type 2 diabetes at baseline, n (%) 34 (0.3) 21 (0.3) 13 (2.0) <.001
Year of cART initiation .28
 2004 163 (2.0) 155 (2.0) 8 (1.2)
 2005 1922 (23.0) 1775 (23.0) 147 (22.9)
 2005 2200 (26.4) 2037 (26.4) 163 (25.3)
 2007 1682 (20.1) 1544 (20.0) 138 (21.5)
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at the end of follow up. The median change in CD4+ count 
from baseline was also higher for younger patients at 6 (112 vs 
94, P = .0002), 12 (151 vs 132, P = .0005), and 24 (181 vs 151, 
P < .001) months (Table 2).
Given the differences observed in the use of NRTI backbone 
at baseline, we further analyzed CD4 response by thymidine-an-
alogue-based NRTI backbone (AZT and 3TC) versus others 
(TDF and ABC). Median CD4+ counts (IQR) were similar at 
months 6 (268 vs 276, P =  .38), 12 (302 vs 303, P =  .92), and 
18 (344 vs 336, P = .36) but differed at 24 months (370 vs 356, 
0.003) for thymidine-analogue NRTI backbone versus others.
The proportion of patients achieving virologic suppres-
sion was significantly higher for older patients at months 6 
(73.9% vs 70.2%, P =  .04) and 24 (74.8% vs 69.6%, P =  .005) 
than for younger patients (Table 2). When we assessed the pro-
portions of all patients who sustained viral suppression from 
month 6 of cART to month 24 (FS), there was no significant 
difference between older and younger patients (15.7 vs 17.0, 
P  =  .41). However, in an adjusted logistic regression model, 
female patients (odds ratio [OR] = 1.24; 95% confidence inter-
val [CI], 1.09–1.40) and those with medication adherence 
>95% (OR = 1.38; 95% CI, 1.22–1.56) were more likely to be 
FS compared with their relevant counterparts. Patients with low 
baseline body mass index ([BMI] OR, 0.72; 95% CI, 0.60–0.87), 
WHO stages III/IV disease (OR, 0.74; 95% CI 0.65–0.84), or 
those lacking formal education (OR, 0.83; 95% CI, 0.60–0.87) 
were less likely than their respective comparators to be FS from 
6 through 24 months.
Loss to follow-up rates were similar for the younger versus 
older age groups (0.59 vs 0.60 per 1000 person years [PY], 
P =  .88). The probability of LTFU between the 2 groups were 
different, with younger patients having a higher likelihood of 
LTFU (log rank P = .04). In a Cox proportional hazard regres-
sion model adjusting for baseline demographic, clinical and 
treatment characteristics (Table 3), older patients (aHR = 0.74; 
95% CI, 0.58–0.93), patients who were FS (aHR = 0.50; 95% CI, 
0.41–0.59), and those with adherence >95% (aHR, 0.62; 95% 
CI, 0.52–0.64) had a lower hazard of LTFU than their respective 
comparator groups. The independent predictors of LTFU were 
male sex (aHR = 1.20; 95% CI, 1.06–1.36), lack of formal edu-
cation (aHR = 1.94; 95% CI, 1.66–2.26), WHO stage III/IV at 
baseline (aHR = 1.43; 95% CI, 1.26–1.63), BMI <18.5 kg/m2 at 
baseline (aHR, 1.23; 95% CI, 1.07–1.42), and experiencing a gap 
in treatment (aHR = 1.90, 95% CI, 1.66–2.18).
Mortality rates were similar for older and younger patients. 
Of 83 documented deaths within the follow-up period, 73 
were aged 15–49 years, whereas 10 were aged ≥50 years, with 
7 (0.1%) dying early (within the 90  days of initiating cART). 
The mortality rate was 0.05 vs 0.03 per 1000PY for older and 
younger patients, respectively (P =  .10). Survival rates among 
those aged ≥50 years were also similar to those aged 15–49 years 
(log rank P = .06; Supplementary Figure). After controlling for 
Figure 2. Box plot of median CD4+ counts from baseline (Mo) through 24 months 
by age group. The box plot used minimum value (lower error bar), the the 25th per-
centile (lower border of the box), the median value/50th percentile (the line in the 
middle of the box), the 75th percentile (the top border of the box), and the maximum 
value (the top error bar).
Characteristics Total (n = 8352) Young (15–49 Years) (n = 7709)
Older (≥50 Years)
(n = 643) P Value
 2008 1450 (17.4) 1339 (17.4) 111 (17.3)
 2009 846 (10.1) 772 (10.0) 74 (11.5)
 2010 85 (1.0) 83 (1.1) 2 (0.3)
NRTI Backbone in cART <.001
 Zidovudine (AZT) 4130 (49.4) 3847 (49.9) 283 (44.0)
 Tenofovir-disoproxil fumarate (TDF) 1816 (21.8) 1626 (21.0) 190 (29.5)
 Stavudine (d4T) 951 (11.4) 888 (11.5) 63 (9.8)
 Abacavir (ABC) 238 (2.8) 222 (2.9) 16 (2.5)
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; cART, combination antiretroviral therapy; CKD-EPI, chronic kidney disease epidemiology collaboration; eGFR, estimated 
glomerular filtration rate; HBsAg, hepatitis B surface antigen; HCVab, hepatitis C virus antibody; HIV, human immunodeficiency virus; IQR, interquartile range; NRTI, nucleoside reverse-tran-
scriptase inhibitor; RNA, ribonucleic acid; SD, standard deviation; WHO, World Health Organization.
aEstimated glomerular filtration rate using the CKD-EPI formula.
bBody mass index.
Table 1. Continued
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socio-demographic (sex, marital status, level of education), 
clinical (WHO stage, BMI), biologic (HBV and HCV coinfec-
tion status, full viral suppression), and behavioral (medication 
adherence and gaps in treatment) characteristics (Table  3), 
male sex (aHR, 1.92; 95% CI, 1.24–2.98), WHO stages III/IV 
at baseline (aHR, 2.70; 95% CI, 1.67–4.36), and having gaps in 
Table 3. Association of Age Group With Risk of LTFU and Death Among (Older vs Younger) HIV-Infected Nigerians Initiating First-Line ART
LTFU Died
Model 1 Model 2 Model 3 Model 4
Characteristic AHR (95% CI) AHR (95% CI) AHR (95% CI) AHR (95% CI) AHR (95% CI)
Age group, 
years Ref Ref Ref Ref Ref
Young (15–49)  
Older (≥50)
0.74 (0.58–0.93)a 1.38 (0.70–2.71) 1.32 (0.70–2.46) 0.74 (0.47–1.16) 0.67 (0.48–0.95)a
Sex, Male 1.20 (1.06–1.36)a 1.92 (1.24–2.98)a 1.12 (0.76–1.64) 1.50 (1.19–1.90)b 1.26 (1.06–1.49)a
No formal education 1.94 (1.66–2.26)b 1.07 (0.48–2.41) 1.74 (1.06–2.85)a 1.95 (1.44–2.64)b 1.86 (1.50–2.32)b
WHO stage III/IV 1.43 (1.26–1.63)b 2.70 (1.67–4.36)b 1.05 (0.68–1.61) 1.36 (1.05–1.75)a 1.33 (1.10–1.59)a
BMI <18.5 kg/m2 1.23 (1.07–1.42)a 1.58 (0.94–2.65) 1.82 (1.21–2.73)a 1.13 (0.86–1.50)a 1.01 (0.82–1.24)a
HBV coinfection 1.11 (0.96–1.28) 1.19 (0.68–2.10) 1.57 (1.02–2.42)a 1.56 (1.19–2.04) 1.39 (1.14–1.70)
HCV coinfected 1.04 (0.89–1.21) - - - -
Fully suppressed 0.52 (0.43–0.64)b 0.14 (0.03–0.61)a 0.62 (0.33–1.13) 0.54 (0.36–0.80)a 0.77 (0.66–0.91)a
Adherence >95% 0.68 (0.60–0.76)b 1.00 (0.64–1.55) 0.65 (0.44–0.94)a 0.63 (0.50–0.80)b 0.77 (0.66–0.91)a
Any gap in care 1.90 (1.66–2.18)b 3.69 (2.35–5.80)b 2.12 (1.39–3.22)b 1.92 (1.47–2.50)b 1.83 (1.51–2.22)b
Abbreviations: AHR, adjusted hazard ratio; ART, antiretroviral therapy; BMI, body mass index; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodefi-
ciency virus; LTFU, loss to follow-up; Ref, reference; WHO, World Health Organization. 
NOTES: Model 1, complete case analysis; Model 2, 10% LTFU imputed as dead; Model 3, 25% LTFU imputed as dead; Model 4, 50% LTFU imputed as dead.
aP < .05.
bP < .001.
Table 2. Follow-Up Data on Treatment From Baseline Through 24 Months of cART for Young and Older Patients Initiating Treatment
Variable Total Young (15–49 Years) Older (≥50 Years) P Value
Days on HIV care, median (IQR) 1541 (1051–2051) 1547 (1056–2052) 1468 (1020–2004) .01
Days on cART, median (IQR) 1610 (1092–2112) 1614 (1093–2114) 1586 (1064–2081) .10
Median CD4+ Cell Increase From Baseline (IQR), Cells/mm3
 Month 6 110 (25–200) 112 (27–202) 94 (2–179) .0002
 Month 12 149 (55–254) 151 (56–256) 132 (43–232) .0005
 Month 18 165 (39–284) 116 (40–286) 153 (30–265) .03
 Month 24 182 (21–312) 185 (24–318) 151 (0–266) <.001
Viral Suppression (% <400 copies/mL)
 Month 6 4807 (70.5) 4424 (70.2) 383 (73.9) .04
 Month 12 4992 (69.1) 4596 (68.9) 396 (71.6) .13
 Month 18 4451 (68.8) 4100 (68.7) 351 (70.8) .24
 Month 24 4200 (70.0) 3867 (69.6) 333 (74.8) .005
Number of Treatment Gaps .47
 None 7330 (87.8) 6760 (87.7) 570 (88.6)
 ≥1 gap 1022 (12.2) 949 (12.3) 73 (11.4)
 ≥95% adherence 4898 (58.6) 4523 (58.7) 375 (58.3) .86
Drug Switch at 6 Month, n (%) .59
 Yes 18 (0.2) 17 (0.2) 1 (0.2)
 No 8334 (99.8) 7692 (99.8) 642 (99.8)
Patient Status at Censoring, n (%)
 Alive (in site) 5765 (69.0) 5320 (69.0) 445 (69.2) .29
 LTFU 1533 (18.4) 1425 (18.4) 108 (16.8)
 Transferred 953 (11.4) 873 (11.4) 80 (12.4) .31
 Died 83 (1.0) 73 (1.0) 10 (1.6)
 Withdrew 18 (0.2) 18 (0.2) 0 (0) .14
Abbreviations: cART, combination antiretroviral therapy; HIV, human immunodeficiency virus; IQR, interquartile range; LTFU, loss to follow up.
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treatment (aHR, 3.69; 95% CI, 2.35–5.80) were the only signif-
icant predictors of mortality. However, being fully virologically 
suppressed reduced the risk of death, with an aHR of 0.14 (95% 
CI, 0.03–0.61).
After imputation of mortality data, 3 additional Cox propor-
tional hazard models were generated to control for the effect of 
missing mortality data as shown in Table 3. Model 1, which is 
the complete case analysis, was unable to detect the predictive 
effect of additional factors such as the lack of formal educa-
tion, hepatitis B coinfection, low BMI, and optimal medica-
tion adherence on mortality. Although the hazard estimates/
function for mortality increased progressively from 1.5 (95% 
CI, 1.00–2.00) for younger and 2.3 (95% CI, 1.10–4.60) for older 
patients (P = .14) using Model 1 to 13.5 (95% CI, 12.4–14.7) for 
younger and 11.3 (95% CI, 8.30–15.2) for older patients using 
Model 4 (P = .52), the risk for mortality remains similar for both 
age groups (Supplementary Table).
DISCUSSION
In this large retrospective evaluation of HIV-infected patients 
in a high burden resource-limited treatment site, we compared 
immunologic, virologic, and clinical outcomes within the first 
2  years of cART among different age groups. Older age was 
associated with reduced CD4+ cell recovery and improved viro-
logic suppression. Differences in LTFU rates were seen when 
comparing young and older patients. Older age was not shown 
to impact the risk of death compared with younger age in our 
study, and this finding differs from previous reports from urban 
and rural African settings [17, 19, 21, 26, 27]. However, we note 
the low number of deaths documented in our cohort.
Data on the effect of age on immune response to cART in our 
study and from other SSA countries [17, 19, 20] is comparable 
to studies from high-income countries [11–13, 15, 28]. Immune 
recovery after cART tends to be slower in older patients, with 
some studies reporting a loss of this advantage with longer 
periods of follow up after an initial slower response [8]. Aging 
has been associated with decreased production of interleukin 
(IL)-2 and its receptors, where the lower responsiveness to IL-2 
has been implicated as a mechanism for compromised T-cell 
function, leading to a shift in T-cell phenotype [29, 30]. It has 
also been reported that a reduced CD4+ response in elderly 
patients may be related to involution of the thymus gland, with 
decreased productivity. Increased age is further associated with 
diminished T-cell functionality, reduced memory T-cell popu-
lations, and fewer numbers of properly functioning CD8+ cyto-
toxic T cells [31, 32].
The goal of cART is sustained suppression of HIV replica-
tion. Our study, as well as other studies reporting results of 
virologic response, shows that older patients have higher rates 
of viral suppression in spite of higher initial viral burden com-
pared with younger patients [8, 14, 15, 17, 33]. Older patients 
also tend to have shorter time to viral suppression, although 
our study did not address this outcome [8]. Better medication 
adherence rates have been reported to play a key role in older 
patients achieving higher viral suppression rates compared with 
younger patients, yet our analyses did not indicate a difference 
in overall adherence in older patients compared with younger 
adults [34]. Our study also showed that female patient’s and 
those with medication adherence rates >95% were more likely 
to be FS, with low rates of sustained virologic suppression 
occurring in both groups. Barriers to optimal adherence among 
younger patients in sub-Saharan Africa have included nondis-
closure to loved ones, fear of stigmatization, substance abuse, 
complexity of drug regimens, and cost of healthcare services in 
countries that do not subsidize treatment. Some of these fac-
tors are dependent on the treatment setting, but they tend to 
overlap where they exist [35, 36]. Efforts to improve medication 
adherence with consequent increase in rates of viral suppres-
sion among younger patients (and subsequent community-level 
viral suppression) should be explored.
Overall, LTFU rates in this study were lower than those 
reported in other studies from Africa, Asia, and various 
resource-rich settings [37]. We found that the hazard of LTFU 
was lower for those aged ≥50  years compared with patients 
aged 15–49 years. Our findings about LTFU in young compared 
with older adults corroborate findings from a study conducted 
using data from 7 African countries [21] and a recent multisite 
study in Nigeria [38]. The higher risk for LTFU among younger, 
compared with older, patients increases their risk for death and 
other adverse outcomes, including their likelihood of transmit-
ting HIV to seronegative sex partners. Effective interventions to 
reduce LTFU for youth could help reduce losses and lower HIV 
incidence in this age group.
Amongst documented deaths, mortality was low for our 
cohort and older age was not found to be a risk factor for mor-
tality. This finding is consistent with reports from Uganda [39] 
and Malawi [18] as well as in the United States [14]. Several 
other studies have reported contrary findings regarding age and 
mortality in settings similar to ours [17, 19, 21] as well as in 
resource-rich settings [11, 16]. Studies reporting higher rates of 
mortality among older patients have attributed this association 
to delayed presentation, more rapid disease progression, as well 
as higher incidence of cART-related adverse reactions. We must 
note that a major limitation in our mortality analyses is that 
mortality data are collected in a passive nature and, therefore, 
mortality is underreported.
This study has some notable strengths. We used routine pro-
gram data from a large urban HIV clinic that provided care to 
a wide variety of patients from different localities. Cohort stud-
ies have the advantage of providing longer follow-up periods 
for a large number of patients in real-life scenario, with greater 
generalizability to target populations and are, therefore, appro-
priate for studying long-term responses of treatment to chronic 
conditions such as HIV. Our results are likely generalizable in 
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settings similar to ours. The large sample size and sociodemo-
graphic characteristics at baseline reflect the profile of patients 
who enroll for care in most sites in sub-Saharan Africa. We also 
note some limitations in the fact that we were somewhat dis-
advantaged by our inability to fully ascertain the true reasons 
for those lost to follow-up, and so it is possible that we overes-
timated LTFU and underestimated mortality. We used imputa-
tion [39] to mitigate this limitation. Our diagnosis of hepatitis 
B and C status was based on presence of surface antigen and 
anti-HCV antibodies only, because the program did not have 
routine access to confirmatory tests. We were also not able to 
assess the impact of other significant variables such as substance 
abuse, smoking, and alcohol use on our outcomes of interest 
due to lack of data. Finally, because this study was a retrospec-
tive analysis, we could not attribute causality to our outcomes.
CONCLUSIONS
In conclusion, clinical management of older persons with HIV 
is an increasingly important issue because of the large impact 
of cART on improved survival. Approaches to improve the out-
comes of older HIV patients in SSA could include interventions 
to optimize CD4+ cell gains on cART. Additional investigation 
in resource-constrained settings is needed to optimize the care 
of this emerging group in light of the presence of other comor-
bidities. With the increased availability and use of cART in 
resource-constrained areas, the number of older persons with 
HIV who are on cART will continue to increase. Increased 
knowledge of the clinical issues that affect older persons with 
HIV is urgently needed in developing countries.
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